Celularity Inc. (CELU)

NCM – Real vaqt narxi. Valyuta: USD

0.62

-0.05 (-6.81%)

Yopilishda: Jun 26, 2026, 4:00 PM EDT

0.69

+0.07 (11.29%)

Bozordan keyin: Jun 26, 2026, 7:43 PM EDT

04.06.2026

Celularity and Fountain Life Announce Availability of Cenplacel-L for Investigational Use Under New Florida Law, Establishing Scalable Pathway for Advancement of Placental-Derived Cell Therapies

FLORHAM PARK, N.J. and ORLANDO, Fla.

03.06.2026

Celularity Releases CEO Letter to Shareholders

FLORHAM PARK, N.J., June 03, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) ("Celularity" or the "Company"), a longevity-focused regenerative and cellular medicine company pioneering placental-derived cellular therapies, today announced that it has posted a Letter to Shareholders from Robert J. Hariri, M.D., Ph.D., Celularity's Founder, Chairman, and Chief Executive Officer, to the Investor Relations section of its website. The letter is also included below.

03.06.2026

Celularity Appoints Rick Gonzalez as Chief Commercial Officer

FLORHAM PARK, N.J., June 03, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity” or the “Company”), a longevity-focused regenerative and cellular medicine company pioneering placental-derived cellular and regenerative therapies, today announced the appointment of Rick Gonzalez as Chief Commercial Officer, effective May 29, 2026.

29.05.2026

Celularity Receives Nasdaq Notice Regarding Form 10-Q

FLORHAM PARK, N.J., May 29, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (the “Company”), a longevity-focused regenerative and cellular medicine company, today announced that it received a notification letter on May 27, 2026, from the Listing Qualifications Department of The Nasdaq Stock Market LLC indicating that, as a result of the Company's delayed filing of its Quarterly Report on Form 10-Q for the period ended March 31, 2026, the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1). Nasdaq Listing Rule 5250(c)(1) requires listed companies to timely file all periodic financial reports with the U.S. Securities and Exchange Commission.

01.05.2026

Celularity Announces Filing of Form 10-K, Regains Nasdaq Compliance and Highlights Continued Strategic Transformation

Company advances focused strategy, strengthens balance sheet and positions business for long-term growth Company advances focused strategy, strengthens balance sheet and positions business for long-term growth

27.04.2026

NEXGEL Appoints Ian Blackman as Chief Financial Officer

Veteran Financial and M&A Leader Appointed to Integrate Acquisition of Celularity, Scale the Business and Accelerate Growth LANGHORNE, Pa., April 27, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced the appointment of Ian Blackman, CPA, as Chief Financial Officer.

21.04.2026

Celularity Announces Closing of Transaction with NexGel

FLORHAM PARK, N.J., April 21, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a longevity-focused regenerative and cellular medicine company, today announced the closing of its previously announced transaction with NexGel, Inc. (“NexGel”), pursuant to which NexGel acquired certain commercial and other assets related to Celularity's biomaterials product portfolio and received an exclusive license to develop and commercialize specified products. The transaction is intended to monetize Celularity's biomaterials portfolio while enabling it to further concentrate resources on advancing its longevity-focused therapeutic pipeline and scalable manufacturing platform.

Videolar

No Data

There is no data to display

Press-relizlar

04.06.2026

Celularity and Fountain Life Announce Availability of Cenplacel-L for Investigational Use Under New Florida Law, Establishing Scalable Pathway for Advancement of Placental-Derived Cell Therapies

FLORHAM PARK, N.J. and ORLANDO, Fla.

03.06.2026

Celularity Releases CEO Letter to Shareholders

03.06.2026

Celularity Appoints Rick Gonzalez as Chief Commercial Officer

29.05.2026

Celularity Inc. (CELU)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Celularity Inc. (CELU)

Celularity and Fountain Life Announce Availability of Cenplacel-L for Investigational Use Under New Florida Law, Establishing Scalable Pathway for Advancement of Placental-Derived Cell Therapies

Celularity Releases CEO Letter to Shareholders

Celularity Appoints Rick Gonzalez as Chief Commercial Officer

Celularity Receives Nasdaq Notice Regarding Form 10-Q

Celularity Announces Filing of Form 10-K, Regains Nasdaq Compliance and Highlights Continued Strategic Transformation

NEXGEL Appoints Ian Blackman as Chief Financial Officer

Celularity Announces Closing of Transaction with NexGel

Videolar

No Data

Press-relizlar

Celularity and Fountain Life Announce Availability of Cenplacel-L for Investigational Use Under New Florida Law, Establishing Scalable Pathway for Advancement of Placental-Derived Cell Therapies

Celularity Releases CEO Letter to Shareholders

Celularity Appoints Rick Gonzalez as Chief Commercial Officer

Celularity Receives Nasdaq Notice Regarding Form 10-Q

Celularity and Fountain Life Announce Availability of Cenplacel-L for Investigational Use Under New Florida Law, Establishing Scalable Pathway for Advancement of Placental-Derived Cell Therapies

Celularity Releases CEO Letter to Shareholders

Celularity Appoints Rick Gonzalez as Chief Commercial Officer

Celularity Receives Nasdaq Notice Regarding Form 10-Q

Celularity Announces Filing of Form 10-K, Regains Nasdaq Compliance and Highlights Continued Strategic Transformation

NEXGEL Appoints Ian Blackman as Chief Financial Officer

Celularity Announces Closing of Transaction with NexGel

Videolar

No Data

Press-relizlar

Celularity and Fountain Life Announce Availability of Cenplacel-L for Investigational Use Under New Florida Law, Establishing Scalable Pathway for Advancement of Placental-Derived Cell Therapies

Celularity Releases CEO Letter to Shareholders

Celularity Appoints Rick Gonzalez as Chief Commercial Officer

Celularity Receives Nasdaq Notice Regarding Form 10-Q

Search stocks

Celularity Inc. (CELU)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Celularity Inc. (CELU)

Celularity and Fountain Life Announce Availability of Cenplacel-L for Investigational Use Under New Florida Law, Establishing Scalable Pathway for Advancement of Placental-Derived Cell Therapies

Celularity Releases CEO Letter to Shareholders

Celularity Appoints Rick Gonzalez as Chief Commercial Officer

Celularity Receives Nasdaq Notice Regarding Form 10-Q

Celularity Announces Filing of Form 10-K, Regains Nasdaq Compliance and Highlights Continued Strategic Transformation

NEXGEL Appoints Ian Blackman as Chief Financial Officer

Celularity Announces Closing of Transaction with NexGel

Videolar

No Data

Press-relizlar

Celularity and Fountain Life Announce Availability of Cenplacel-L for Investigational Use Under New Florida Law, Establishing Scalable Pathway for Advancement of Placental-Derived Cell Therapies

Celularity Releases CEO Letter to Shareholders

Celularity Appoints Rick Gonzalez as Chief Commercial Officer

Celularity Receives Nasdaq Notice Regarding Form 10-Q

Celularity and Fountain Life Announce Availability of Cenplacel-L for Investigational Use Under New Florida Law, Establishing Scalable Pathway for Advancement of Placental-Derived Cell Therapies

Celularity Releases CEO Letter to Shareholders

Celularity Appoints Rick Gonzalez as Chief Commercial Officer

Celularity Receives Nasdaq Notice Regarding Form 10-Q

Celularity Announces Filing of Form 10-K, Regains Nasdaq Compliance and Highlights Continued Strategic Transformation

NEXGEL Appoints Ian Blackman as Chief Financial Officer

Celularity Announces Closing of Transaction with NexGel

Videolar

No Data

Press-relizlar

Celularity and Fountain Life Announce Availability of Cenplacel-L for Investigational Use Under New Florida Law, Establishing Scalable Pathway for Advancement of Placental-Derived Cell Therapies

Celularity Releases CEO Letter to Shareholders

Celularity Appoints Rick Gonzalez as Chief Commercial Officer

Celularity Receives Nasdaq Notice Regarding Form 10-Q